本文選題：制度移植 + 孤兒藥管理制度��； 參考：《中國衛(wèi)生事業(yè)管理》2017年07期

【摘要】：目的:構(gòu)建符合我國國情的孤兒藥管理制度,促進(jìn)孤兒藥的生產(chǎn)與供給。方法:基于制度移植理論,運用文獻(xiàn)研究法對美國、歐盟、日本的孤兒藥管理制度的主要內(nèi)容和制度特色進(jìn)行比較和分析。結(jié)果:在孤兒藥的管理上,美國、歐盟和日本在制度設(shè)計中均涉及諸多激勵措施,給孤兒藥的研發(fā)和上市帶來積極影響。結(jié)論:推動制度供給外生變量,制定孤兒藥管理的法律法規(guī),成立孤兒藥認(rèn)證和管理機(jī)構(gòu),完善醫(yī)保制度等配套制度。
[Abstract]:Objective: to construct the management system of orphan drugs in China to promote the production and supply of orphan drugs. Methods: based on the theory of institutional transplantation, the main contents and characteristics of Orphan Drug Administration system in USA, EU and Japan were compared and analyzed by literature research. Results: in the management of orphan drugs, the United States, the European Union and Japan all involved many incentives in the system design, which had a positive impact on the development and marketing of orphan drugs. Conclusion: promote the system to supply exogenous variables, formulate the laws and regulations of Orphan Drug Management, set up Orphan Drug Certification and Management Organization, perfect the medical insurance system and other supporting systems.
【作者單位】： 南京中醫(yī)藥大學(xué)衛(wèi)生經(jīng)濟(jì)管理學(xué)院;
【基金】：教育部哲學(xué)社會科學(xué)研究重大課題攻關(guān)項目”基本醫(yī)療服務(wù)保障法制化研究”(編號:14JZD025)
【分類號】：R951
，

本文編號：1826285